Grisk O
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study Roos I, Sharmin S, Horakova D, Kubala Havrdova E, Libertinova J, Vachova M, Alroughani R, Boz C, Rous Z, Buzzard K, Skibina O, Peterka M, Hradilek P, Mares M, Coles A, Brown JWL, Eichau Madueo S, Foschi M, Prevost J, Terzi M, Prat A, Girard M, Meca-Lallana JE, John N, Blanco Y, van der Walt A, Butzkueven H, Recmanova E, Laureys G, Ampapa R, Macdonell R, Pavelek Z, Khoury SJ, D'Amico E, Gerlach O, Van Pesch V, Maimone D, Romero-Ferrando B, McCombe PA, Mrabet S, Willekens B, Crdenas-Robledo S, Ramo-Tello C, Stourac P, Houskova J, Shaygannejad V, Hodgkinson S, Cartechini E, Kermode AG, Fabis-Pedrini M, Carroll WM, Slee M, Snchez-Menoyo JL, Al-Asmi A, Mathey G, Giannesini C, Michel L, Ciron J, De Sze J, Ruet A, Kwiatkowski A, Zephir H, Papeix C, Lebrun-Frenay C, Moreau T, Berger E, Clavelou P, Pelletier J, Casez O, Bourre B, Wahab A, Magy L, Camdessanch JP, Doghri I, Tchikviladze M, Sellebjerg F, Romme Christensen J, Jensen HB, Illes Z, Bramow S, Rasmussen PV, Stilund ML, Schfer J, Kant M, Weglewski A, Vukusic S, Magyari M, Laplaud DA, Kalincik T
& Filmus, J
Safe exercise involves avoiding temperature extremes and choosing appropriate activities based on age and health status
Results can vary, with some individuals experiencing benefits immediately while others may notice improvements over several days or weeks
N1-methyl-pseudouridine is incorporated with higher fidelity than pseudouridine in synthetic RNAs
